SGD Pharma has released its 2024 Sustainability Report, highlighting record-breaking progress in environmental and social responsibility. The company earned an impressive 87/100 Platinum rating from EcoVadis, its highest ever, ranking SGD Pharma among the top 1% of glass manufacturers worldwide.
Key environmental gains include upgraded Science Based Targets initiative (SBTi) goals, now aiming for a 42% reduction in emissions by 2030, up from 35%. In global disclosure benchmarks, SGD Pharma scored B (Climate Change) and B- (Water Security) in the CDP programs.
All global manufacturing sites, across France, China, India, and Germany, are now certified to ISO 14001, ISO 45001, and ISO 50001 standards. Additionally, the Zhanjiang (ZJ) plant in China achieved a milestone of 1,000 accident-free days, and 10,000 mangrove trees were planted in China during 2024.
For the first time, the report aligns with the Corporate Sustainability Reporting Directive (CSRD), supported by a Double Materiality Assessment (DMA) and gap analysis. These evaluations covered SGD Pharma’s full value chain, identifying sustainability risks and opportunities for responsible growth.
The company conducted a living wage analysis across all facilities to ensure equitable compensation. A global anti-corruption risk map and Ethics & Compliance training were also deployed to reinforce governance and integrity.
SGD Pharma reaffirms its support of the UN Global Compact, integrating its ten principles into all operations. With measurable outcomes and clear targets, the 2024 report confirms that sustainability is central to SGD Pharma’s global strategy.
Source: SGD Pharma with additional information added by Glass Balkan